B. Selected peer-reviewed publications (in chronological order). Do not include publications submitted or in preparation. (selected from 261 peer reviewed publications)


assessment of aerosolized red tide toxins (brevetoxins) and asthma. Environ Health Perspect. 2009;117:1095-100


C. Research Support. List selected ongoing or completed (during the last three years) research projects (federal and non-federal support). Begin with the projects that are most relevant to the research proposed in this application. Briefly indicate the overall goals of the projects and your role (e.g. PI, Co-Investigator, Consultant) in the research project. Do not list award amounts or percent effort in projects.

NIH 1 PO1 ES 10594-01 (Co-Investigator)
Title: Effects of Inhaled Florida Red Tide Brevetoxins
Project Title: Smooth Muscle Effects of Airborne Brevetoxin in the Airway
This project evaluates the respiratory effects of red tide-derived brevetoxins in experimental animals and human subjects.

Asthma Clinical Research Center (Principal Investigator)
Agency: American Lung Association
This program is a nationwide clinical asthma research network of centers with the necessary infrastructure for multi-center studies of the natural course of asthma and the effects of therapeutic interventions in children and
adults.
Title: School-Based Asthma Intervention Program
Agency: NIH/NIAID
Period: 09/30/94 - 08/31/03
This project tests the hypothesis that a school-based intervention program will reduce morbidity in young minority children with asthma.

**1RO1HL58086-01 (PI)**
Title: Alpha-Adrenergic Regulation of Airway Blood Flow
Agency: NIH NHLBI
Period: 04/01/98-03/31/03
The major goal is to test the hypothesis that the inflammatory increase in alpha-adrenergic vascular responsiveness is due to upregulated alpha-adrenergic signaling in vascular smooth muscle or decreased alpha-adrenergic generation of endothelial relaxing factors, or both.

**NIH NIEHS 1PO1 ES 10594 ZES1-** Project Title: “Effects of inhaled Florida red tide brevetoxins” 7/1/00-6/30/10
Co-Investigator.

**Florida RC1 grant 24248**- The airway microbiome in COPD. 1/10/10-1/9/12. ($ 749,000). Principle investigator

**Academic Grants from Industry (P.I.):**
- Acute effects of inhaled glucocorticoids on airway blood flow (GSK, 1999; $92,000).
- Comparative vasoconstrictive actions of inhaled glucocorticoids (GSK, 2000; $49,000).
- Racemic and R-albuterol on airway blood flow (Sepracor, 2000; $50,000).
- Effect of anti-inflammatory therapy on airway blood flow in asthma (Merck, 2003; $48,000).
- Airway blood flow reactivity in smokers with or without COPD. (GSK, 2004; $52,000).
- Low-dose steroid pretreatment potentiates adrenergic airway and airway vascular responses in the airway (Sepracor, 2004; $50,000).
- Role of airway blood flow in exercise-induced asthma (Merck 2005; $59,000).
- Endothelial function in the airway of smokers (GSK 2005; $54,000).
- Effect of budesonide on formoterol disposal (AstraZeneca, 2005; $89,406).
- Interactive smooth muscle effects of salmeterol and fluticasone in the airway (GSK 2006; $50,625).
- pH dependent drug transport mechanisms in the airway: implications for inhaled beta-2 adrenergic agonist therapy in asthma (AstraZeneca 2007; $166,703)
- Effect of an inhaled glucocorticoid on endothelial function in cigarette smokers (GSK 2008; $73,831)
- Acute effect of momethasone on beta-adrenergic airway and airway vascular relaxation in moderately severe asthmatics (Schering-Plow 2010; $55,000)
- Carrier-mediated absorption and clearance of tiotropium in the airway (BI 2009; $110,000)
- Effect of an Inhaled Glucocorticoid-long-acting beta adrenergic agonist on Endothelial Function in COPD (GSK 2010; $62,500)

**Acute vasoconstrictive effect of budesonide in the airway of patients with asthma (AZ 2010, $70,000)**
Airway and pulmonary vascular endothelial function in healthy smokers: Effect of inhaled glucocorticosteroid treatment (GSK 2013; $125,000)
Effect of Roflumilast on Airway Blood Flow as an Expression of Airway Inflammation in COPD (Forest 2013; $199,000)